US Patent Issued to Beijing Wisdomab Biotechnology, GENRIX (Shanghai) Biopharmaceutical Co.Ltd., Chongqing Genrix Biopharmaceutical on Oct. 6 for "Antibodies against human TSLP and use thereof" (Chinese Inventors)

ALEXANDRIA, Va., Oct. 6 -- United States Patent no. 12,753,227, issued on Oct. 6, was assigned to Beijing Wisdomab Biotechnology Co. Ltd. (Beijing), GENRIX (Shanghai) Biopharmaceutical Co.Ltd. (Shanghai) and Chongqing Genrix Biopharmaceutical Co. Ltd. (Chongqing, China).

"Antibodies against human TSLP and use thereof" was invented by Xueping Zhang (Beijing), Zhigang Liu (Beijing), Xiaowei Zhou (Beijing), Junjie Hu (Beijing), Xiaobo Hao (Beijing) and Yulan Liu (Beijing).

According to the abstract* released by the U.S. Patent & Trademark Office: "A bispecific antibody and a monoclonal antibody against human thymic stromal lymphopoietin (TSLP), and a use thereof."

The patent was filed on June 17, 2021, under Application No. 18/264,070.

*Fo...